Format

Send to

Choose Destination
Circulation. 2018 Feb 27;137(9):989-991. doi: 10.1161/CIRCULATIONAHA.117.031847.

Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".

Author information

1
Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City (M.K.).
2
University of North Carolina, Chapel Hill (M.A.C.).
3
Georgetown University Medical Center, Washington, DC (A.Z.F.).
4
University of Liverpool, United Kingdom (J.P.W.).
5
University of Leicester, United Kingdom (K.K.).
6
University of Ulm, Germany (R.W.H.).
7
Karolinska Institutet, Stockholm, Sweden (A.N., N.H.).
8
University of Oslo, Norway (K.I.B.).
9
Oslo University Hospital, Norway (K.I.B.).
10
Steno Diabetes Center, Copenhagen, Denmark (M.E.J.).
11
National Institute of Public Health, Southern Denmark University (M.E.J.).
12
Statisticon AB, Uppsala, Sweden (M.T.).
13
AstraZeneca, Gaithersburg, MD (N.A.).
14
AstraZeneca, Oslo, Norway (J.B.).
15
AstraZeneca Gothenburg, Sweden (N.H.).
16
AstraZeneca, Cambridge, United Kingdom (P.F.).

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center